Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/ou_press/corrigendum-to-percutaneous-short-term-active-mechanical-support-56weYgD0Mh
References (0)
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Oxford University Press
- Copyright
- Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
- ISSN
- 0195-668X
- eISSN
- 1522-9645
- DOI
- 10.1093/eurheartj/ehx634
- Publisher site
- See Article on Publisher Site
Abstract
1780 C.S.P. Lam et al. 14. Kang S-H, Park JJ, Choi D-J, Yoon C-H, Oh I-Y, Kang S-M, Yoo B-S, Jeon E-S, Kim 22. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez J-J, Cho M-C, Chae SC, Ryu K-H, Oh B-H. Prognostic value of NT-proBNP in AF, Butler J, Yancy CW, Fonarow GC. Outcomes in patients with heart failure heart failure with preserved versus reduced EF. Heart 2015;101:1881–1888. . with preserved, borderline, and reduced ejection fraction in the Medicare popu- 15. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, . lation. Am Heart J 2014;168:721–730.e3. Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and 23. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese short-term prognosis in acute destabilized heart failure: an international pooled G, Dahlstro ¨ m U, Lund LH. Significance of ischemic heart disease in patients with analysis of 1256 patients: the International Collaborative of NT-proBNP Study. . heart failure and preserved, midrange, and reduced ejection fraction: a nation- Eur Heart J 2006;27:330–337. wide cohort study. Circulation 2017;10:e003875. 16. van Veldhuisen DJ, Linssen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen 24. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, JGP, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir in heart failure patients with preserved and reduced ejection fraction. J Am Coll . O, Logeart D, Dahlstro ¨ m U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Cardiol 2013;61:1498–1506. Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, 17. Cleland JGF,TaylorJ,FreemantleN,Goode KM,Rigby AS,Tendera M. Relationship Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; On behalf between plasma concentrations of N-terminal pro brain natriuretic peptide and the . of the Heart Failure Association of the European Society of Cardiology. characteristics and outcome of patients with a clinical diagnosis of diastolic heart fail- European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): ure: a report from the PEP-CHF study. Eur J Heart Fail 2012;14:487–494. 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, 18:613–625. McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of . 25. Lam CSP, Teng T-HK, Tay WT, Anand I, Zhang S, Shimizu W, Narasimhan C, baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions Park SW, Yu C-M, Ngarmukos T, Omar R, Reyes EB, Siswanto BB, Hung C-L, with irbesartan treatment effects in patients with heart failure and preserved Ling LH, Yap J, MacDonald M, Richards AM. Regional and ethnic differences ejection fraction: findings from the I-PRESERVE trial. Circulation 2011;4:569–577. . among patients with heart failure in Asia: the Asian sudden cardiac death in heart 19. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B- failure registry. Eur Heart J 2016;37:3141–3153. type natriuretic peptide levels and in-hospital mortality in acute decompensated 26. Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, Miller A, heart failure. J Am Coll Cardiol 2007;49:1943–1950. Teerlink JR, White M, McKelvie RS, Komajda M, Zile MR, McMurray JJ, Massie B. 20. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. . The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart B-type natriuretic peptide strongly reflects diastolic wall stress in patients with Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial chronic heart failure: comparison between systolic and diastolic heart failure. (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC 2015;3: J Am Coll Cardiol 2006;47:742–748. . 429–441. 21. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, 27. Chioncel O, Mebazaa A, Harjola V-P, Coats AJ, Piepoli MF, Crespo-Leiro MG, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, EF, O’meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Miani D, Filippatos G, Maggioni AP; On behalf of the ESCHFL-TRI. Clinical phe- Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection . notypes and outcome of patients hospitalized for acute heart failure: the ESC fraction. N Engl J Med 2014;370:1383–1392. Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242–1254. doi:10.1093/eurheartj/ehx634 Corrigendum Online publish-ahead-of-print 26 October 2017 ................................................................................................ .................................................................. Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta- analysis of randomized trials [Eur Heart J (2017); doi:10.1093/eurheartj/ehx363]. The authors of the above article wish to inform readers that the following correction has been made post-publication: in the conclusion, the follow- ing sentence has been corrected to include the word ‘in’: ‘Results of this collaborative meta-analysis do not support the unselected use of active MCS in patients with CS complicating AMI.’ Published on behalf of the European Society of Cardiology. All rights reserved. V The Author 2017. For permissions, please email: journals.permissions@oup.com.
Journal
European Heart Journal – Oxford University Press
Published: Oct 26, 2017